2019
Randomized placebo-controlled trial of galantamine in individuals with cocaine use disorder
DeVito EE, Carroll KM, Babuscio T, Nich C, Sofuoglu M. Randomized placebo-controlled trial of galantamine in individuals with cocaine use disorder. Journal Of Substance Use And Addiction Treatment 2019, 107: 29-37. PMID: 31757262, PMCID: PMC6918721, DOI: 10.1016/j.jsat.2019.08.009.Peer-Reviewed Original ResearchConceptsCocaine use disorderSignificant treatment group differencesUse disordersEfficacy of galantamineTreatment-seeking cocaine usersCurrent cocaine use disordersGroup differencesCocaine use outcomesSample of individualsTreatment group differencesComorbid opioid use disorderMethadone-maintained individualsMemory capacityAbstinent individualsCocaine useCognitive improvementCognitive outcomesCocaine use reductionCognitive functionUse outcomesCocaine usersGalantamine groupIndividualsDisordersInitial promise
2017
Atomoxetine in abstinent cocaine users: Sex differences
DeVito EE, Herman AI, Konkus NS, Zhang H, Sofuoglu M. Atomoxetine in abstinent cocaine users: Sex differences. Data In Brief 2017, 14: 566-572. PMID: 28861456, PMCID: PMC5568877, DOI: 10.1016/j.dib.2017.08.011.Peer-Reviewed Original ResearchAtomoxetine in abstinent cocaine users: Cognitive, subjective and cardiovascular effects
DeVito EE, Herman AI, Konkus NS, Zhang H, Sofuoglu M. Atomoxetine in abstinent cocaine users: Cognitive, subjective and cardiovascular effects. Pharmacology Biochemistry And Behavior 2017, 159: 55-61. PMID: 28716656, PMCID: PMC5573182, DOI: 10.1016/j.pbb.2017.07.002.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic Uptake InhibitorsAdultAffectAtomoxetine HydrochlorideAttentionCocaine-Related DisordersCognitionCross-Over StudiesDose-Response Relationship, DrugDouble-Blind MethodFemaleHemodynamicsHumansInhibition, PsychologicalMaleMemory, Short-TermMiddle AgedNeuropsychological TestsSex CharacteristicsConceptsCocaine use disorderMeasures of attentionAbstinent cocaine usersSubjective drug effectsHuman laboratory studiesResponse inhibitionCognitive enhancementAbstinent individualsCognitive enhancersBehavioral treatmentAddictive processClinical populationsAtomoxetineCognitive impairmentNorepinephrine transporter inhibitorUse disordersCocaine usersCardiovascular effectsMoodMedication effectsPoor clinical outcomeDose-dependent effectIndividualsDrug effectsMemory